Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 25 studies | 33% ± 12% | |
macrophage | 21 studies | 23% ± 8% | |
monocyte | 17 studies | 30% ± 10% | |
non-classical monocyte | 17 studies | 30% ± 12% | |
conventional dendritic cell | 12 studies | 27% ± 12% | |
endothelial cell | 9 studies | 26% ± 6% | |
fibroblast | 8 studies | 22% ± 5% | |
neutrophil | 6 studies | 22% ± 6% | |
epithelial cell | 6 studies | 34% ± 16% | |
dendritic cell | 6 studies | 26% ± 13% | |
smooth muscle cell | 5 studies | 20% ± 3% | |
pericyte | 5 studies | 23% ± 5% | |
connective tissue cell | 5 studies | 21% ± 3% | |
myeloid cell | 5 studies | 36% ± 11% | |
ciliated cell | 5 studies | 28% ± 6% | |
basal cell | 5 studies | 24% ± 9% | |
mononuclear phagocyte | 4 studies | 29% ± 8% | |
myofibroblast cell | 4 studies | 18% ± 2% | |
intermediate monocyte | 4 studies | 38% ± 19% | |
GABAergic neuron | 4 studies | 27% ± 10% | |
glutamatergic neuron | 4 studies | 36% ± 11% | |
leukocyte | 4 studies | 21% ± 3% | |
alveolar macrophage | 3 studies | 17% ± 2% | |
interneuron | 3 studies | 28% ± 10% | |
neuron | 3 studies | 30% ± 10% | |
oligodendrocyte | 3 studies | 18% ± 1% | |
plasmacytoid dendritic cell | 3 studies | 19% ± 4% | |
oligodendrocyte precursor cell | 3 studies | 22% ± 1% | |
secretory cell | 3 studies | 25% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1069.36 | 1445 / 1445 | 100% | 30.74 | 183 / 183 |
ovary | 100% | 864.64 | 180 / 180 | 100% | 24.07 | 430 / 430 |
lung | 100% | 1214.17 | 576 / 578 | 100% | 27.35 | 1155 / 1155 |
intestine | 100% | 1072.58 | 966 / 966 | 100% | 25.21 | 525 / 527 |
bladder | 100% | 1035.10 | 21 / 21 | 100% | 25.81 | 502 / 504 |
breast | 100% | 1004.09 | 459 / 459 | 99% | 22.71 | 1112 / 1118 |
brain | 99% | 867.15 | 2619 / 2642 | 100% | 17.95 | 705 / 705 |
prostate | 100% | 899.30 | 244 / 245 | 99% | 18.52 | 498 / 502 |
uterus | 99% | 1070.98 | 169 / 170 | 99% | 26.07 | 456 / 459 |
thymus | 100% | 913.59 | 651 / 653 | 99% | 17.65 | 599 / 605 |
adrenal gland | 100% | 1525.92 | 258 / 258 | 97% | 13.89 | 223 / 230 |
kidney | 99% | 782.46 | 88 / 89 | 98% | 15.79 | 882 / 901 |
stomach | 97% | 636.01 | 347 / 359 | 100% | 27.77 | 286 / 286 |
skin | 99% | 992.47 | 1796 / 1809 | 94% | 15.27 | 445 / 472 |
pancreas | 83% | 351.00 | 271 / 328 | 99% | 20.29 | 176 / 178 |
liver | 89% | 435.50 | 201 / 226 | 91% | 10.35 | 368 / 406 |
adipose | 100% | 1194.99 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 30.53 | 29 / 29 |
muscle | 100% | 5588.55 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1455.60 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 18.21 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.47 | 1 / 1 |
blood vessel | 100% | 1069.41 | 1332 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 3438.20 | 915 / 929 | 0% | 0 | 0 / 0 |
heart | 98% | 1747.34 | 842 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 75% | 7.43 | 60 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000209 | Biological process | protein polyubiquitination |
GO_1902916 | Biological process | positive regulation of protein polyubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0030514 | Biological process | negative regulation of BMP signaling pathway |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_1904262 | Biological process | negative regulation of TORC1 signaling |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0061631 | Molecular function | ubiquitin conjugating enzyme activity |
GO_0005515 | Molecular function | protein binding |
Gene name | UBE2D1 |
Protein name | Ubiquitin-conjugating enzyme E2 D1 (EC 2.3.2.23) ((E3-independent) E2 ubiquitin-conjugating enzyme D1) (EC 2.3.2.24) (E2 ubiquitin-conjugating enzyme D1) (Stimulator of Fe transport) (SFT) (UBC4/5 homolog) (UbcH5) (Ubiquitin carrier protein D1) (Ubiquitin-conjugating enzyme E2(17)KB 1) (Ubiquitin-conjugating enzyme E2-17 kDa 1) (Ubiquitin-protein ligase D1) E2 ubiquitin-conjugating enzyme (EC 2.3.2.23) |
Synonyms | UBC5A SFT UBCH5 UBCH5A |
Description | FUNCTION: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins . In vitro catalyzes 'Lys-48'-linked polyubiquitination . Mediates the selective degradation of short-lived and abnormal proteins. Functions in the E6/E6-AP-induced ubiquitination of p53/TP53. Mediates ubiquitination of PEX5 and auto-ubiquitination of STUB1, TRAF6 and TRIM63/MURF1 . Ubiquitinates STUB1-associated HSP90AB1 in vitro . Lacks inherent specificity for any particular lysine residue of ubiquitin . Essential for viral activation of IRF3 . Mediates polyubiquitination of CYP3A4 . . |
Accessions | ENST00000373910.9 A0A087WW00 P51668 ENST00000615793.1 |